{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:58:29Z","timestamp":1791885509694,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012410","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000}}],"reference-count":163,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012410.pub2","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T09:46:34Z","timestamp":1526377594000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Ee Teng","family":"Goh","sequence":"first","affiliation":[{"name":"Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; Rowland Hill Street Hampstead London UK NW3 2PF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S","family":"Stokes","sequence":"additional","affiliation":[{"name":"Saarland University Medical Centre; Department of Medicine II; Kirrberger Str. 100 Homburg\/Saar Germany 66421"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep S","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Dayanand Medical College & Hospital; Department of Gastroenterology; Tagore Nagar, Civil Lines Ludhiana Punjab India 141001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Vilstrup","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital; Department of Hepatology and Gastroenterology; N\u00f8rrebrogade 44 Aarhus 8200 N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle 30 Hvidovre Denmark 2650"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha Y","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Medicine, Royal Free Campus, University College London; UCL Institute for Liver & Digestive Health; Rowland Hill Street Hampstead London UK NW3 2PF"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"10.1002\/14651858.CD012410.pub2-BIB0001|cit1","first-page":"666","article-title":"Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy","volume":"21","author":"Abid","year":"2011","journal-title":"Journal of the College of Physicians and Surgeons Pakistan"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0002|cit2","first-page":"84","article-title":"Efficacy of infusion of L-ornithine L-aspartate in cirrhotic patients with portosystemic encephalopathy: a placebo controlled study [abstract]","volume":"42","author":"Abid","year":"2005","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0003|cit3","first-page":"684","article-title":"L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy","volume":"18","author":"Ahmad","year":"2008","journal-title":"Journal of the College of Physicians and Surgeons Pakistan"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0004|cit4","first-page":"1249A","article-title":"Oral L-ornithine L-aspartate (LOLA) in cirrhotic patients with minimal hepatic encephalopathy (MHE): final results of a randomized double-blind placebo-controlled trial (PORTO ALEGRE STUDY) [abstract]","volume":"54","author":"Alvares-da-Silva","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/hepr.12235","article-title":"Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial","volume":"44","author":"Alvares-da-Silva","year":"2014","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0006|cit6","unstructured":"Silva GD Alvares-Da-Silva M Araujo AD Vicenzi J Magnus A Bazzanella F Therapeutic efficacy of oral L-ornithine-L-aspartate on minimal encephalopathy (PORTOALEGRE) www.lume.ufrgs.br\/bitstream\/handle\/10183\/38555\/000793877.pdf?sequence=1"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Bai M He C Yin Z Niu J Wang Z Qi X Randomised clinical trial: L-ornithine-l-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS Alimentary Pharmacology & Therapeutics 2014 63 71 dx.doi.org\/10.1111\/apt.12795","DOI":"10.1111\/apt.12795"},{"issue":"Suppl","key":"10.1002\/14651858.CD012410.pub2-BIB0008|cit8","first-page":"1899","article-title":"L-ornithine L-aspartate is as effective as nonabsorbable disaccharides in the management of acute hepatic encephalopathy [abstract]","volume":"54","author":"Blanco Vela","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0009|cit9","first-page":"718","article-title":"Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy","volume":"25","author":"Chen","year":"2005","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0010|cit10","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0011|cit11","first-page":"669","article-title":"Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - results of a randomized, placebo-controlled double-blind multicentre trial","volume":"3","author":"Feher","year":"1997","journal-title":"Medical Science Monitor"},{"issue":"Suppl","key":"10.1002\/14651858.CD012410.pub2-BIB0012|cit12","first-page":"65","article-title":"Placebo-controlled, double-blind evaluation of L-ornithine\u2013L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE) [abstract]","volume":"30","author":"Fleig","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2007.05.019","article-title":"Assessment of low-grade hepatic encephalopathy: a critical analysis","volume":"47","author":"Kircheis","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0014|cit14","unstructured":"Hasan I Iskandar M Budihusodo U Effect of L-ornithine-L-aspartate on liver cirrhosis patients with low-grade hepatic encephalopathy [abstract] Hepatology International 2012 295 dx.doi.org\/10.1007\/s12072-011-9333-4"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(17)30362-8","article-title":"A randomized, double-blind, clinical trial comparing lactulose, L-ornithine L-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding","volume":"66","author":"Higuera-de la Tijera","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0016|cit16","first-page":"508","article-title":"Clinical control study of L-ornithine-L-aspartate in the treatment of subclinical hepatic encephalopathy","volume":"4","author":"Hong","year":"2003","journal-title":"West China Medical Journal"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0017|cit17","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0019|cit18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis","year":"1997","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0018|cit19","first-page":"221","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study [abstract]","volume":"8","author":"Kircheis","year":"1997","journal-title":"Hepatology Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0020|cit20","first-page":"S818","article-title":"Clinical efficacy of L-ornithine L-aspartate in the prevention of altered oral glutamine challenge in patients with minimal hepatic encephalopathy: a pilot study [abstract]","volume":"138","author":"Maldonado","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0021|cit21","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0022|cit22","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0023|cit23","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0024|cit24","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD012410.pub2-BIB0025|cit25","first-page":"310A","article-title":"L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data (MRZ 90004-8806)","volume":"32","author":"Delcker","year":"2000","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0026|cit26","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0027|cit27","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD012410.pub2-BIB0028|cit28","first-page":"310A","article-title":"L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data (MRZ 90004-8807)","volume":"32","author":"Delcker","year":"2000","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0029|cit29","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0030|cit30","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0031|cit31","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD012410.pub2-BIB0032|cit32","first-page":"310A","article-title":"L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data (MRZ 90004-8901)","volume":"32","author":"Delcker","year":"2000","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0033|cit33","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0034|cit34","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0035|cit35","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0036|cit36","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0037|cit37","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0038|cit38","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MEG.0b013e32834696f5","article-title":"A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy","volume":"23","author":"Mittal","year":"2011","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0040|cit40","unstructured":"Mittal VV Sharma P Sharma B Sarin SK Treatment of minimal hepatic encephalopathy: a randomized controlled trial comparing lactulose, probiotics & L-ornithine L-aspartate with placebo [abstract] Hepatology (Baltimore, Md.) 2009 471A"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0041|cit41","first-page":"18","article-title":"The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition","volume":"43","author":"Ndraha","year":"2011","journal-title":"Acta Medica Indonesiana"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0042|cit42","first-page":"35","article-title":"Oral L-ornithine-L-aspartate (LOLA) for patients with overt hepatic encephalopathy treated with lactulose; a randomized, double-blinded, placebo-controlled trial [abstract]","volume":"4","author":"Nimanong","year":"2010","journal-title":"Hepatology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0168-8278(10)60182-1","article-title":"Oral L-ornithine-L-aspartate (LOLA) for patients with overt hepatic encephalopathy treated with lactulose; a randomized, double-blinded, placebo-controlled trial [abstract]","volume":"52","author":"Nimanong","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0168-8278(10)60184-5","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patents with cirrhosis and hepatic encephalopathy [abstract]","volume":"52","author":"Oruc","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1665-2681(19)31989-1","article-title":"Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study","volume":"5","author":"Poo","year":"2006","journal-title":"Annals of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0168-8278(07)61679-1","article-title":"Efficacy and safety of L-ornithine L-aspartate (LOLA) administration. Open label randomized controlled trial versus lactulose in cirrhotic patients with hyperammoniemic hepatic encephalopathy [abstract]","volume":"46","author":"Poo","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0047|cit47","first-page":"65","article-title":"Treatment of minimal hepatic encephalopathy: a randomized control trial comparing L ornithine L aspartate with placebo [abstract]","volume":"29","author":"Puri","year":"2010","journal-title":"Indian Journal of Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S0168-8278(08)60312-8","article-title":"Prospective randomized pilot trial of I.V. L-ornithine L-aspartate vs. placebo on postural control in patients with cirrhosis [abstract]","volume":"48","author":"Schmid","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1478-3231.2010.02213.x","article-title":"A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis","volume":"30","author":"Schmid","year":"2010","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0050|cit50","first-page":"275","article-title":"Minimal hepatic encephalopathy: effect of rifaximin, probiotics and L-ornithine L-aspartate","volume":"27","author":"Sharma","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/1319-3767.136975","article-title":"Effect of rifaximin, probiotics, and L-ornithine L-aspartate on minimal hepatic encephalopathy: a randomized controlled trial","volume":"20","author":"Sharma","year":"2014","journal-title":"Saudi Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0052|cit52","unstructured":"NCT01722578 L-ornithine L-aspartate in overt hepatic encephalopathy (HEAL) clinicaltrials.gov\/ct2\/show\/NCT01722578 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Sidhu SS Sharma BC Goyal O Kishore H Kaur N L-ornithine L-aspartate in bouts of overt hepatic encephalopathy Hepatology (Baltimore, Md.) 2018 700 10 10.1002\/hep.29410","DOI":"10.1002\/hep.29410"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","article-title":"Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study","volume":"28","author":"Stauch","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jceh.2017.01.009","article-title":"Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate","volume":"7","author":"Pasha","year":"2017","journal-title":"Journal of Clinical and Experimental Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jceh.2017.05.115","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: a double blind randomized controlled trial of L-ornithine L-aspartate vs placebo","volume":"7","author":"Varakanahalli","year":"2017","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0057|cit57","first-page":"385","article-title":"Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels","volume":"21","author":"Zhou","year":"2013","journal-title":"Chinese Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0058|cit58","first-page":"135","article-title":"Decreased hospital stay with the use of L-ornithine L- aspartate (LOLA) in patients with hepatic encephalopathy","volume":"2","author":"Abdo-Francis","year":"2010","journal-title":"Revista de Gastroenterolog\u00eda de M\u00e9xico"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1053\/j.gastro.2009.02.050","article-title":"Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study","volume":"136","author":"Acharya","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0060|cit60","first-page":"37","article-title":"Therapeutic efficacy of L-ornithine L-aspartate in patients with hepatic encephalopathy","volume":"10","author":"Aidrus","year":"2015","journal-title":"Pakistan Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0061|cit61","unstructured":"Badea M Gavrilescu O Dranga M Mihai C Prelipcean CC Lactulose alone versus lactulose and L-ornithine L-aspartate for the prophylaxis of hepatic encephalopathy in acute variceal bleeding: a prospective case control study Falk Symposium 199 2015 18"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1015468112686","article-title":"Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine-L-aspartate treatment - results of a pilot study","volume":"17","author":"Delcker","year":"2002","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Grover VP McPhail MJ Wylezinska M Crossey MM Fitzpatrick JA Southern L A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy Metabolic Brain Disease 2017 77 86","DOI":"10.1007\/s11011-016-9881-3"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0064|cit64","first-page":"258","article-title":"Oral L-ornithine-L-aspartate is safe and effective in patients with intractable hepatic encephalopathy - the NZ liver transplant unit experience","volume":"4","author":"Lim","year":"2010","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e31828726e1","article-title":"Modulation of neural activation following treatment of hepatic encephalopathy","volume":"80","author":"McPhail","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0066|cit66","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy (MRZ 90004-8701) International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0067|cit67","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0068|cit68","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report: MRZ 90004-9902 2000"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0069|cit69","first-page":"5590","article-title":"Controlled study of the effect of an orally administered ammonia lowering amino acid (ornithine-aspartate) on liver and pancreas function in liver cirrhosis patients","volume":"30","author":"M\u00fcting","year":"1980","journal-title":"Therapiewoche"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0070|cit70","article-title":"Controlled study evaluating the effect of high dose oral ornithineaspartate on hepatic encephalopathy in patients with cirrhosis with or without surgical shunts","volume-title":"Aminos\u00e4uren- und Ammoniakstoffwechsel bei Leberinsuffizienz. Grundlagen und therapeutische Folgerungen","author":"Reikowski","year":"1982"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0071|cit71","first-page":"11","article-title":"The efficacy of L-ornithine L-aspartate granules and normal protein diet in minimal hepatic encephalopathy with malnutrition","volume":"11","author":"Ndraha","year":"2010","journal-title":"Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11586700-000000000-00000","article-title":"Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study","volume":"31","author":"Ong","year":"2011","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0073|cit73","unstructured":"Popa I Badea M Gavrilescu O Dranga M Chiosa AM Didita A Normix alone vs. normix + L-ornithine L-aspartate for the treatment of patients with minimal hepatic encephalopathy Falk Symposium 199 2015 69"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.47.4.571","article-title":"Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial","volume":"47","author":"Rees","year":"2000","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0075|cit75","first-page":"459","article-title":"The effect of L-ornithine L-aspartate on TIPS patients undergoing glutamine challenge?","volume-title":"Advances in Hepatic Encephalopathy & Metabolism in Liver Disease: Proceedings of the 9th International Symposium on Ammonia","volume":"64","author":"Rees","year":"1997"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0076|cit76","article-title":"Controlled study evaluating the effect of high dose ornithin-aspartate on hepatic encephalopathy in cirrhosis with or without surgical shunts","volume-title":"Aminos\u00e4uren- und Ammoniakstoffwechsel bei Leberinsuffizienz. Grundlagen und therapeutische Folgerungen","author":"Reikowski","year":"1982"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0077|cit77","unstructured":"Delcker A Goertelmeyer R Comes G. Meta-analysis L-ornithine L-aspartate IV Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report MRZ 90004-8603"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0168-8278(05)80553-7","article-title":"Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design","volume":"19","author":"Staedt","year":"1993","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0080|cit79","first-page":"2185","article-title":"Effect of BCAA and LOLA combination as late evening snacks on nutritional status and minimal hepatic encephalopathy in cirrhosis [abstract]","volume":"7","author":"Tenda","year":"2013","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0079|cit80","first-page":"151","article-title":"The effect of branched chain amino acids and L-ornithine L-aspartate combination as the late evening snacks on nutritional status and minimal hepatic encephalopathy in liver cirrhosis","volume":"13","author":"Tenda","year":"2012","journal-title":"Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S1118","DOI":"10.1016\/S0016-5085(16)33773-8","article-title":"Motor deficit of hand and arm movements in manifest hepatic encephalopathy before and after therapy with L-ornithin-L-aspartat [abstract]","volume":"150","author":"Tiller","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0973-6883(11)60126-6","article-title":"Pathogenesis, diagnosis, and treatment of hepatic encephalopathy","volume":"1","author":"Atluri","year":"2011","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jgh.12142","article-title":"L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials","volume":"28","author":"Bai","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1053\/j.gastro.2008.07.021","article-title":"Inhibitory control test for the diagnosis of minimal hepatic encephalopathy","volume":"135","author":"Bajaj","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/hep.23216","article-title":"Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","author":"Bajaj","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement","volume":"33","author":"Bajaj","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/ajg.2011.157","article-title":"The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers","volume":"106","author":"Bajaj","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1665-2681(19)31609-6","article-title":"Determination of ammonia concentrations in cirrhosis patients - still confusing after all these years?","volume":"10","author":"Blanco Vela","year":"2011","journal-title":"Annals of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1665-2681(19)31608-4","article-title":"Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy","volume":"10","author":"Blanco Vela","year":"2011","journal-title":"Annals of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0093|cit93","unstructured":"Brozek J Oxman A Sch\u00fcnemann H GRADEpro 2008"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/B978-0-444-62619-6.00034-3","article-title":"Hepatic encephalopathy in alcoholic cirrhosis","volume":"125","author":"Butterworth","year":"2014","journal-title":"Handbook of Clinical Neurology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0096|cit96","unstructured":"Butterworth RF L-ornithine-L-aspartate for the treatment of hepatic encephalopathy in cirrhosis: an update on mechanisms of action and therapeutic efficacy International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) meeting; 2017 Mar 9-11; New Delhi, India 2017"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"S714","DOI":"10.1016\/S0168-8278(18)31688-X","article-title":"Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: A systematic reviewand meta-analysis of randomised controlled trials","volume":"68","author":"Butterworth","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1572-0241.2001.03552.x","article-title":"Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?","volume":"96","author":"Cadranel","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1111\/j.1440-1746.1997.tb00512.x","article-title":"Evoked potentials in liver diseases","volume":"12","author":"Chu","year":"1997","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D'Amico","year":"1986","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"Jongh","year":"1992","journal-title":"Gastroenterology"},{"issue":"4 (Part 2)","key":"10.1002\/14651858.CD012410.pub2-BIB0104|cit104","first-page":"310A","article-title":"L-ornithine-L-aspartine vs placebo in the treatment of hepatitis encephalopathy: meta-analysis of randomised placebo-controlled trials using individual data","volume":"32","author":"Delcker","year":"2000","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0105|cit105","unstructured":"Delcker A Goertelmeyer R Comes G Meta-analysis L-ornithine L-aspartate IV Unpublished Clinical Study Report MRZ 90004-9902"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1440-1746.1995.tb01041.x","article-title":"Figure connection test: a universal test for assessment of mental state","volume":"10","author":"Dhiman","year":"1995","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"Dwan","year":"2008","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases","volume":"61","author":"American Association for the Study of Liver Diseases","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)37027-2","article-title":"Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels","volume":"283","author":"Gebhardt","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0112|cit112","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About Cochrane (Cochrane Review Groups (CRGs)) 2017 Issue 6. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/hep.510280108","article-title":"Subclinical hepatic encephalopathy impairs daily functioning","volume":"28","author":"Groeneweg","year":"1998","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1478-3231.2009.02030.x","article-title":"Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Gu\u00e9rit","year":"2009","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0168-8278(00)80110-5","article-title":"Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?","volume":"32","author":"Haussinger","year":"2000","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1740774508091600","article-title":"Imputation methods for missing outcome data in meta-analysis of clinical trials","volume":"5","author":"Higgins","year":"2008","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0118|cit118","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0119|cit119","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1016\/j.clinph.2016.03.027","article-title":"New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy","volume":"127","author":"Jackson","year":"2016","journal-title":"Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"The clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1440-1746.2008.05582.x","article-title":"L-ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis","volume":"24","author":"Jiang","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/jhep.2002.30957","article-title":"Critical flicker frequency for quantification of low-grade hepatic encephalopathy","volume":"35","author":"Kircheis","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2007.05.019","article-title":"Assessment of low-grade hepatic encephalopathy: a critical appraisal","volume":"47","author":"Kircheis","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2009.08.003","article-title":"Hepatic encephalopathy and fitness to drive","volume":"137","author":"Kircheis","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11011-011-9242-1","article-title":"Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease","volume":"26","author":"Lauridsen","year":"2011","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/B:MEBR.0000043980.74574.eb","article-title":"Blood ammonia levels and hepatic encephalopathy","volume":"19","author":"Lockwood","year":"2004","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/B:MEBR.0000043977.11113.2a","article-title":"Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach","volume":"19","author":"Montagnese","year":"2004","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"28S","DOI":"10.1592\/phco.30.pt2.28S","article-title":"Pharmacoeconomics of hepatic encephalopathy","volume":"5 Pt 2","author":"Neff","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/0140-6736(91)92920-W","article-title":"Regional cerebral blood flow and cognitive function in patients with chronic liver disease","volume":"337","author":"O'Carroll","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jhep.2016.05.004","article-title":"Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy","volume":"65","author":"Olesen","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD012410.pub2-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000035.pub2","article-title":"Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions","author":"Page","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(57)90005-3","article-title":"The electroencephalograph in liver disease","volume":"273","author":"Parsons-Smith","year":"1957","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1665-2681(19)31610-2","article-title":"Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure","volume":"10","author":"Perez Hernandez","year":"2011","journal-title":"Annals of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012410.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1478-3231.2009.02009.x","article-title":"Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Randolph","year":"2009","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0137|cit137","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/ajg.2010.413","article-title":"Minimal hepatic encephalopathy is associated with falls","volume":"106","author":"Roman","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/A:1020613314572","article-title":"L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action","volume":"13","author":"Rose","year":"1998","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/hep.510300311","article-title":"L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure","volume":"30","author":"Rose","year":"1999","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bmj.282.6260.263","article-title":"A 20-year prospective study of cirrhosis","volume":"282","author":"Saunders","year":"1981","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovic","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/BF01367675","article-title":"Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive","volume":"26","author":"Schomerus","year":"1981","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1020645110880","article-title":"Neuropsychological aspects of portal-systemic encephalopathy","volume":"13","author":"Schomerus","year":"1998","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MEG.0b013e3283341b7d","article-title":"Predictors of non response to lactulose in patients with cirrhosis and hepatic encephalopathy","volume":"22","author":"Sharma","year":"2010","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1590\/S0004-28032009000300019","article-title":"A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment","volume":"46","author":"Soarez","year":"2009","journal-title":"Arquivos de Gastroenterologia"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lt.21593","article-title":"Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation","volume":"15","author":"Sotil","year":"2009","journal-title":"Liver Transplantation"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0149|cit149","unstructured":"Stata Corp Stata 14 2007"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","article-title":"In hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transplantation"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02098881","article-title":"Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy","volume":"9","author":"Taylor-Robinson","year":"1994","journal-title":"Metabolic Brain Disease"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness. A practical scale","volume":"2","author":"Teasdale","year":"1974","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0154|cit154","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-196509000-00001","article-title":"The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration","volume":"44","author":"Victor","year":"1965","journal-title":"Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012410.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000051415","article-title":"Diagnosis of encephalopathy","volume":"59","author":"Weissenborn","year":"1998","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0168-8278(01)00026-5","article-title":"Neuropsychological characterization of hepatic encephalopathy","volume":"34","author":"Weissenborn","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1478-3231.2010.02302.x","article-title":"Interorgan ammonia metabolism in liver failure: the basis of current and future therapies","volume":"31","author":"Wright","year":"2011","journal-title":"Liver International"},{"issue":"8","key":"10.1002\/14651858.CD012410.pub2-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012334","article-title":"Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy","author":"Zacharias","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012410.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1478-3231.2012.02830.x","article-title":"Prognostic indicators of survival in patients with compensated and decompensated cirrhosis","volume":"32","author":"Zipprich","year":"2012","journal-title":"Liver International"},{"issue":"10","key":"10.1002\/14651858.CD012410.pub2-BIB0162|cit162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012410","article-title":"L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy","author":"Stokes","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012410.pub2-BIB0163|cit163","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007344","article-title":"L-ornithine-L-aspartate for hepatic encephalopathy","author":"Yuan","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012410.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T11:01:19Z","timestamp":1751626879000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012410.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":163,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012410.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733243259.793573493","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]}}}